Spots Global Cancer Trial Database for Study of Regorafenib in Patients With Advanced Myeloid Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Official Title: Phase I Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Study ID: NCT03042689

Conditions

Acute Myeloid Leukemia

Interventions

Regorafenib

Study Description

Brief Summary: This research study is studying a drug as a possible treatment for advanced myeloid malignancies including AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MPN (myeloproliferative neoplasms) The intervention involved in this study is: -Regorafenib (Stivarga)

Detailed Description: This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Regorafenib for this specific disease but it has been approved for other uses. In this research study, the investigators are looking for the best dose of Regorafenib to treat the participant's disease with. Researchers will also look at how effective the study drug is in treating the participant's disease and if any side effects occur.